// Reference=MNI
// Ceceli A O, 2020: Attention-Deficit/Hyperactivity Disorder (ADHD)
// Subjects=25
-12	-14	-20
-14	-34	-20
-12	-16	-24
-30	-38	-18
6	-26	-34
-8	-38	-16
-32	-26	0
-46	-12	18
-38	2	-8
-62	2	8
-58	-14	18
-38	4	-26
-46	-8	0
-30	-4	-28
8	16	14
-8	16	68
12	62	34
0	56	-8
-46	-58	32
-50	-72	32
50	-66	44
62	-54	40
40	-78	-26

// Ceceli A O, 2020: Healthy Controls
// Subjects=25
-12	-14	-20
-14	-34	-20
-12	-16	-24
-30	-38	-18
6	-26	-34
-8	-38	-16
-32	-26	0
-46	-12	18
-38	2	-8
-62	2	8
-58	-14	18
-38	4	-26
-46	-8	0
-30	-4	-28
-24	34	50
-40	24	48
-12	60	34
6	26	-16
-6	26	-16
2	58	-14
-46	-68	38
-54	-64	30
40	-74	-28

// Pretus C, 2020: Distractor > Baseline, ADHD > Healthy Controls
// Pretus C, 2020: Non-distractor > Baseline, ADHD < Healthy Controls
// Subjects=21
6	45	-24
18	-30	60
9	21	66

// Salmi J, 2020: Attention-Deficit Hyperactivity Disorder (ADHD)
// Subjects=39
58	-14	-18
24	-82	-26
12	-60	38
26	-82	-28
-12	-56	32
52	-28	-16
-28	-76	-44
12	54	-8
16	-32	-6
-50	30	-2
6	4	42
20	-6	-26
2	-56	-34
-28	62	4
-30	-6	56
36	-62	34
30	60	12
34	2	48
22	0	62
38	32	14
-8	-74	34
10	38	26
-48	-50	44
-22	-72	42

// Salmi J, 2020: Healthy Controls
// Subjects=18
58	-14	-18
24	-82	-26
12	-60	38
26	-82	-28
-12	-56	32
52	-28	-16
-28	-76	-44
12	54	-8
16	-32	-6
-50	30	-2
6	4	42
20	-6	-26
2	-56	-34

// Deming P, 2020: Fear > Neutral
// Deming P, 2020: Fear > (Anger + Happiness + Sadness)
// Subjects=94
-37	-78	31
-30	-64	52
9	-19	-15
5	-50	56
-30	13	-15
30	-75	28
-37	-8	45
33	-43	52
9	-64	52
30	-85	14
-26	-36	-11
-40	-33	52

// Massaccesi C, 2021: Controls (CTR) > Autism Spectrum Disorder (ASD)
// Massaccesi C, 2021: ASD > CTR
// Subjects=20
0	-92	4
-2	-90	22
44	-62	4
46	14	28
-32	-10	66
6	12	56
-18	-100	-2

// Vandewouw M M, 2020: Typically Developing (TD)
// Subjects=93
52	34	30
60	-40	4
-28	34	28
14	4	14
-40	10	-4
-16	-6	-12
-20	-86	6
24	-54	-10
28	-76	-2
58	-38	4
4	-62	28
8	56	24
-46	-8	-18
-32	-78	-4
44	-62	-8
50	-66	-2
-26	-90	6
42	40	38
-42	36	30
66	-6	14
-64	-16	34
34	-64	-40

// Vandewouw M M, 2020: Autism Spectrum Disorder (ASD)
// Subjects=107
-4	-6	-10
58	-22	-8
58	-44	26
-20	-86	6
24	-54	-10
28	-76	-2
44	-34	-4
26	20	8
-50	-54	18
-32	-78	-4
44	-62	-8
50	-68	0
-60	-4	44
-6	-76	6
66	-6	14
-64	-16	34
34	-64	-40

// Bashford-Largo J, 2021: Generalized Anxiety Disorder (GAD)
// Subjects=20
32.62	-10.51	62.24
-18.63	-16.91	66.71
-51.08	-1.4	22.29
3.8	-7	68.96
-6.57	43.33	-8.74
13.29	-74.24	24.31
19.91	-48.91	62.26
-15.92	-61.63	-16.56
32.62	-10.51	62.24
-18.64	-13.73	66.44
6.86	-1.92	51.77
-6.25	-41.26	-1.65
18.42	-59.89	2.97
23.13	-45.46	65.28

// Bashford-Largo J, 2021: Healthy Controls
// Subjects=34
32.62	-10.51	62.24
-18.63	-16.91	66.71
-51.08	-1.4	22.29
3.8	-7	68.96
-6.57	43.33	-8.74
13.29	-74.24	24.31
19.91	-48.91	62.26
-15.92	-61.63	-16.56
32.62	-10.51	62.24
-18.64	-13.73	66.44
6.86	-1.92	51.77
-6.25	-41.26	-1.65
18.42	-59.89	2.97
23.13	-45.46	65.28
32.62	-10.51	62.24
-18.63	-16.91	66.71
3.8	-7	68.96
-6.57	43.33	-8.74
13.29	-74.24	24.31
19.91	-48.91	62.26
-15.92	-61.63	-16.56
32.65	-13.43	65.83
-18.61	-13.48	69.76
3.8	-7	68.96
-9.47	-38.11	-1.88
13.29	-74.24	24.31
19.91	-48.91	62.26
-15.92	-61.63	-16.56
32.62	-10.51	62.24
-18.64	-20.33	63.65
3.8	-7	68.96
-6.28	-41.52	-4.97
3.73	-70.35	34.13
23.09	-42.55	61.69

// Bashford-Largo J, 2021: GAD comorbid with Major Depressive Disorder (MDD)
// Subjects=15
32.62	-10.51	62.24
-18.63	-16.91	66.71
-51.08	-1.4	22.29
3.8	-7	68.96
-6.57	43.33	-8.74
13.29	-74.24	24.31
19.91	-48.91	62.26
-15.92	-61.63	-16.56

// Bashford-Largo J, 2021: Subgroup of GAD, Excluding Participants on 
// Stimulants
// Subjects=31
32.62	-10.51	62.24
-18.63	-16.91	66.71
3.8	-7	68.96
-6.57	43.33	-8.74
13.29	-74.24	24.31
19.91	-48.91	62.26
-15.92	-61.63	-16.56

// Bashford-Largo J, 2021: Subgroup of GAD, Excluding Participants on 
// Anti-psychotics
// Subjects=31
32.65	-13.43	65.83
-18.61	-13.48	69.76
3.8	-7	68.96
-9.47	-38.11	-1.88
13.29	-74.24	24.31
19.91	-48.91	62.26
-15.92	-61.63	-16.56

// Bashford-Largo J, 2021: Subgroup of GAD, Excluding Participants on SSRIs
// Subjects=24
32.62	-10.51	62.24
-18.64	-20.33	63.65
3.8	-7	68.96
-6.28	-41.52	-4.97
3.73	-70.35	34.13
23.09	-42.55	61.69

// Bashford-Largo J, 2021: Group (Healthy Controls, GAD) x Reinforcement 
// (Reward, Punishment)
// Subjects=51
0.17	-1.61	15.02
22.39	9.41	-9.58
-22.12	32.8	49.2
-15.5	-1.28	62.01
0.59	-3.84	68.74
6.96	-27.3	53.9
-57.72	6.02	-5.02
-67.1	-31.08	11.58
-18.92	-95.78	-3.62
51.53	-69.72	-3.27
29.39	-73.37	34.09
25.87	-79.9	-8.82
-48.23	31.2	-10.59

// Collin G, 2021: Familial High-Risk Psychosis (FHR)
// Subjects=15
-6	-62	32
16	-40	26
-20	-34	-8

// Collin G, 2021: Healthy Controls
// Subjects=19
-4	36	-8
16	-40	26
-20	-34	-8

// Cui H, 2020: Heartbeat > Fixation, Generalized Anxiety Disorder (GAD) > 
// Healthy Controls (HC)
// Cui H, 2020: Pure tones > Fixation, HC > GAD
// Cui H, 2020: Heartbeat > Pure tones, GAD > HC
// Subjects=30
-33	0	18
45	-87	3
-21	48	30
-9	39	9
48	-18	60
-39	-39	12
0	-45	39
-36	-24	24
-35	0	18
27	-12	75
30	-12	18

// Frangos E, 2021: Control > Baseline during Heat Stimulation, All 
// Participants
// Frangos E, 2021: Placebo > Baseline during Heat Stimulation, All 
// Participants
// Frangos E, 2021: Control > Placebo during Heat Stimulation, All 
// Participants
// Frangos E, 2021: Control > Baseline during Anticipation, All Participants
// Frangos E, 2021: Placebo > Baseline during Anticipation, All Participants
// Frangos E, 2021: Placebo > Control during Anticipation, All Participants
// Subjects=32
28	65	39
39	68	34
49	70	53
60	72	38
53	21	27
28	17	43
37	43	70
74	52	44
18	51	45
40	59	38
18	65	35
40	67	33
49	73	51
27	74	34
64	54	39
52	20	29
31	16	43
39	44	70
76	51	44
15	49	47
53	12	37
37	14	39
26	55	42
27	70	38
20	49	45
79	50	44
39	14	38
32	50	32
15	63	36
55	14	38
34	17	32
62	17	39
32	17	38

// Gonzalez-Vivas C, 2020: Healthy Controls
// Subjects=13
-28	16	58
-12	46	44
-46	8	34
-32	16	34
-38	16	-24
48	34	-16
-38	40	34
-64	-32	8
62	-12	10
52	2	50
-20	-8	-20
28	-66	-26
-40	-6	40
-52	-42	26
4	31	-71
-66	-28	-4
62	-12	-10
-40	26	0
52	4	50
46	22	26
52	30	-2
10	2	66
-28	-16	-14
-54	18	12

// Gonzalez-Vivas C, 2020: Psychosis
// Subjects=13
-28	16	58
-12	46	44
-46	8	34
-32	16	34
-38	16	-24
48	34	-16
-38	40	34
-64	-22	-2
62	-14	-8
52	26	18
-52	-40	26
22	-4	-22
64	-38	26
-50	-52	22
-8	10	-2
22	-1	-19
-64	-22	-2
64	-24	-2
-48	20	22
54	16	18
52	26	-6
-25	1	-19
-6	32	48
62	-38	24
26	8	-28

// Schmidt A, 2020: Placebo > Oxytocinergic (OT), Social Emotion > Control
// Schmidt A, 2020: Belief > Control
// Schmidt A, 2020: Social Emotion > Control
// Schmidt A, 2020: Placebo > OT, Belief > Control
// Schmidt A, 2020: Placebo < OT, Belief > Control
// Schmidt A, 2020: OT > Placebo, Social Emotion > Control
// Subjects=27
-48	18	-4
-30	36	-8
-56	16	2
48	26	-4
32	34	-8
30	-10	-28
20	-10	-16
58	-42	-4
66	-36	-2
64	-44	-10
42	-22	34
36	-26	42
42	-28	58
-60	-38	6
-26	-70	8
-24	-62	12
-34	-10	-4
12	-22	-12
-8	-42	-22
2	-62	38
-46	-60	32
-40	-56	52
-46	-52	38
-30	16	42
-36	10	50
52	-68	14
56	-64	22
-54	22	26
-42	22	26
-32	22	20
-56	24	16
-48	42	-2
-46	36	-14
56	-56	16
48	-60	10
48	-68	-4
-6	54	28
-8	18	58
-6	54	40
-60	-54	8
-52	-60	26
-48	14	-34
56	26	2
46	30	-10
56	24	20
-2	-60	32
12	-78	-34
28	-78	-36
32	-70	-32
-14	4	12
-10	14	6
50	24	40
48	10	46
-18	-76	-36
16	6	12
22	-2	64
26	-20	14
-18	8	48
-36	-8	2
-50	-22	34
-44	-14	5
-16	-40	30
14	-44	30
14	64	24
10	58	34
-14	-88	32
-20	0	36
14	-84	38
-48	10	-20
-18	-24	30
56	56	20

// Jin H, 2020: Panic Disorder (PD) > Healthy Controls (HC), Hearbeat > Rest
// Jin H, 2020: PD > HC, Pure tones > Rest
// Subjects=18
28	-68	26
-28	-74	-10
-26	-62	30
-16	-84	-8
-32	-54	50
-24	-30	-2
-2	32	52
-54	-24	50
42	-44	38
28	2	56
-2	36	30
46	16	34
48	34	18
32	-54	40
-38	18	34
26	-60	-50

// Lopes F L, 2021: Panic Disorder (PD)
// Subjects=12
-39	-6	-13
51	-6	9
-26	53	5
39	1	27
-56	-46	40
-22	55	0
-36	0	-12
57	-3	24

// Lopes F L, 2021: Healthy Controls (HC)
// Subjects=14
-31	20	-7
-27	-5	-5
-54	1	21
-53	3	24
-7	47	-8

// Araneda R, 2021: Auditory Modality: Beat > No beat
// Araneda R, 2021: Auditory Modality: Early Blindness > Sighted Controls (SC)
// Araneda R, 2021: Auditory Modality: Interaction (Beat vs No beat x EB vs 
// SC)
// Araneda R, 2021: Vibro-tactile Modality: Beat > No beat
// Araneda R, 2021: Vibro-tactile Modality: EB > SC
// Araneda R, 2021: Vibro-tactile Modality: Interaction (Beat vs No beat x EB 
// vs SC)
// Subjects=12
62.28	-27.25	22.04
29.96	-58.79	-25.13
23.58	7.45	6.19
-8.03	-7.92	58.03
-11.52	18.81	32.4
-27.63	-1.86	14.25
-30.44	-50.58	45.13
-40.48	40.58	27.57
-49.81	-2.6	48.02
-42.68	10.22	6.72
-49.89	-42.98	21.3
62.06	-8.7	0.41
39.46	19.2	-8.36
39.53	36.35	6.93
-5.17	-41.08	0.55
-43.35	-35.06	40.63
-53.27	-51.4	-4.72
-54.24	-70.18	0.21
23.74	-76.57	-6.84
7.76	-82.76	-2.79
46.17	-66.67	-4.58
-1.94	-73.81	-10.12
-43.47	-72.52	10.32
-43.56	-76.72	-2.71
31.64	-42.58	60.48
30.08	-14.72	7.97
26.76	43.39	16.52
-21.24	-5.34	10.01
-37.09	-23.36	26.2
-50.18	13.35	6.54
17.2	-41.72	-9.69
23.94	-67.92	22.54
8.09	-46.41	54.38
-.7	-77.55	10.25
-27.54	-60.33	1.31
-27.68	-41.99	-9.15
62.06	11.11	8.79
42.72	46.14	9.42
42.7	3.1	-10.39
29.96	23.6	8.11
14.28	-2.47	43.93
4.84	-.73	67.31
55.83	-66.18	0.84
-8.21	26.46	48.45
-40.59	-6.65	-5.27
-51.22	33.4	18.25
-50.18	8.86	3.57

// Hufner K, 2021: Blind Subjects
// Subjects=11
2	32	28
-22	-80	18
-18	-64	18
-8	-92	22
-9	-95	21
-10	-58	4
34	-34	74
24	-82	16
22	-86	18
-22	-82	-10
16	-66	-10
-34	0	66
-38	10	58
-48	0	56
-22	-80	18
28	-82	16
2	26	30
-46	-42	-28
-14	-20	76
-14	-42	76
-14	-28	78
-12	-52	74
-16	-38	76
16	-26	78
-66	-50	2
-64	-62	10
4	38	52
42	52	24

// Hufner K, 2021: Healthy Controls
// Subjects=12
2	32	28
-22	-80	18
-18	-64	18
-8	-92	22
-9	-95	21
-10	-58	4
34	-34	74
24	-82	16
22	-86	18
-22	-82	-10
16	-66	-10

// Kikuchi H, 2021: Dissociative Amnesia Patient #1
// Subjects=1
28	60	16
50	24	-10
8	8	66
10	-18	74
0	-90	0
-50	20	-8
-66	-40	34
28	8	34
34	-36	-34
38	-64	-50
8	-64	-24
-32	4	50
-30	-10	-12
-46	-16	30
-20	-26	12
-20	-52	72
-36	-76	32
64	-32	40
54	28	-6
42	14	38
-38	48	20
-50	40	-8

// Kikuchi H, 2021: Dissociative Amnesia Patient #2
// Subjects=1
28	60	16
50	24	-10
8	8	66
10	-18	74
0	-90	0
-50	20	-8
-66	-40	34
28	8	34
34	-36	-34
38	-64	-50
8	-64	-24
-32	4	50
-30	-10	-12
-46	-16	30
-20	-26	12
-20	-52	72
-36	-76	32
64	-32	40
30	48	30
-30	60	28
-34	-48	-44
-4	-68	4
-36	-68	-30
-8	-90	-22
-4	-94	12
32	-6	-18
32	-84	-2
-42	-72	20
-28	-88	-10
30	50	30
6	2	54
12	-80	44
-36	54	26
-26	-68	-26
14	16	-14
26	-4	-18
40	-10	-42
54	-14	58
28	-92	-2
0	46	-22
-18	-96	-8

// Doose A, 2020: Time Point 1 < Time Point 2
// Doose A, 2020: Time Point 1 > Time Point 2
// Subjects=22
22	-98	14
-54	-68	32
56	-56	25
6	-54	20
8	54	26

// Lloyd D M, 2021: Subgroup of Nonspecific Low Back Pain, High levels of Pain 
// Behavior (WS-H)
// Subjects=13
-42	-50	50
-52	-44	42
-38	-56	50
-28	-64	38
-22	-30	58
-4	-22	28
-12	-20	50
56	-44	18
50	-52	16
44	-62	4
42	-60	6
-4	-24	48
-22	-32	48
8	-46	62
22	-38	64
6	-98	14
3	12	0
42	40	8
0	40	4
-12	52	9
-4	-80	46
-12	-82	44
14	-68	48
6	-78	10
62	6	36
10	-82	54
-66	-22	28
-12	-16	-18
60	6	36
64	-6	36
50	-40	12
10	-82	32

// Lloyd D M, 2021: Subgroup of Nonspecific Low Back Pain, Low levels of Pain 
// Behavior (WS-L)
// Subjects=16
-4	-24	48
-22	-32	48
8	-46	62
22	-38	64
6	-98	14
3	12	0
42	40	8
0	40	4
-12	52	9
-4	-80	46
-12	-82	44
14	-68	48
6	-78	10
62	6	36
10	-82	54
-66	-22	28
-12	-16	-18
60	6	36
64	-6	36
50	-40	12
10	-82	32

// Lul¨¦ D, 2021: Anorexia Patients
// Subjects=11
-5	-29	42
31	-44	-12
17	-4	16
2	32	48
38	28	-6
-5	50	-3

// Lul¨¦ D, 2021: Healthy Controls
// Subjects=11
-5	-29	42
31	-44	-12
17	-4	16
2	32	48
38	28	-6

// Noda T, 2021: Anorexia Nervosa
// Subjects=23
10	-68	38
46	24	42
-30	20	-6
-2	20	62
-22	-96	-10
14	-96	-2
22	-40	-6
42	4	26
46	-52	30
34	12	-6
-10	-76	38
-6	-8	2
-42	24	-42
30	-76	10
-2	-72	6
-2	-56	22
-18	-68	-10
-2	-76	30
-34	-16	50
-22	12	34
58	-12	14
62	4	26
-6	0	58
54	-24	42

// Noda T, 2021: Healthy Controls
// Subjects=17
-30	24	-2
30	16	-10
62	-48	34
-2	-72	6
-2	-56	22
-18	-68	-10
-2	-76	30
-46	-28	50
58	-20	34
62	4	26
-54	0	22
10	-56	-14
-18	-28	6
-14	-68	-18

// Stopyra M A, 2021: Anorexia Nervosa (AN)
// Subjects=25
-6	-49	14
-15	-4	22
21	5	26
-6	-55	10
-36	-82	-2
-33	-43	38
-27	-49	50
-33	-49	-18
-3	-58	22
-9	-40	-2
-18	56	10
-6	35	-18
-15	44	6

// Stopyra M A, 2021: Healthy Controls (HC)
// Subjects=25
-6	-55	10
-36	-82	-2
-33	-43	38
-27	-49	50
-33	-49	-18
-3	-58	22
-9	-40	-2
-18	56	10
-6	35	-18
-15	44	6

// Suttkus S, 2021: Anorexia Nervosa (AN)
// Subjects=16
26	1	-18
24	-16	-15
6	-55	48.5
-1.5	-61	51.5
-54	-40	23
-61.5	-40	11
-67.5	-29.5	6.5
-7.5	-46	-43
-39	-58	-14.5
-7.5	8	-2.5
37.5	-80.5	-1
37.5	-88	-8.5
27	-91	-13
-28.5	-4	-8.5
-42	-2.5	3.5
-24	21.5	5
57	-44.5	30.5
43.5	-37	50
-24	-44.5	59
-37.5	-44.5	44
0	35	15.5
13.5	33.5	23
-10.5	35	6.5
-25.5	-5.5	57.5
-61.5	-13	-7
-49.5	-26.5	-13
-30	44	20
-22.5	36.5	23

// Suttkus S, 2021: Healthy Controls (HC)
// Subjects=21
26	1	-18
24	-16	-15
45	-13	40
2	11	40
1	10	39
-3	3.5	41
-5	-42	53
17	17	-3
-32	26	5
0	-7	7
-3	-28	-19
35	26	2
-5	-85	17
9	-13	2
-2	13	1
-26	41	40
23	-45	-49
-36	8	49
-63	-33	-9
-20	16	-1
3	35	52
5	10	28
56	34	5
-53	-52	31
12	10	-13
21	-7	-12
0	-66	47
50	-34	-3
6	-55	48.5
-1.5	-61	51.5
-54	-40	23
-61.5	-40	11
-67.5	-29.5	6.5
-7.5	-46	-43
-39	-58	-14.5
-7.5	8	-2.5
37.5	-80.5	-1
37.5	-88	-8.5
27	-91	-13
-28.5	-4	-8.5
-42	-2.5	3.5
-24	21.5	5
57	-44.5	30.5
43.5	-37	50
-24	-44.5	59
-37.5	-44.5	44
0	35	15.5
13.5	33.5	23
-10.5	35	6.5
-25.5	-5.5	57.5
-61.5	-13	-7
-49.5	-26.5	-13
-30	44	20
-22.5	36.5	23

// Tan W, 2020: Chronic Low Back Pain (CLBP)
// Subjects=14
27	-33	-42
51	12	0
9	66	24
69	-21	18
0	-48	72
24	69	15
-57	-45	-18
57	24	18
0	-51	21
-51	21	36
-48	-60	48
63	-30	30
0	-3	72
27	-30	-21
24	69	15
-24	-81	39
9	-54	3
57	39	-6

// Tan W, 2020: Healthy Controls
// Subjects=20
57	18	-6
-57	9	-3
-33	57	27
-57	-54	48
27	-30	-21
24	69	15
-24	-81	39
9	-54	3
57	39	-6

// Benetti S, 2021: Hearing groups: Horizontal + Radial > Static
// Benetti S, 2021: Deaf group: Horizontal + Radial > Static
// Benetti S, 2021: Deaf > Hearing: Horizontal + Radial > Static
// Benetti S, 2021: Deaf & Hearing: Horizontal > Stochastic
// Benetti S, 2021: Deaf & Hearing: Radial > Stochastic
// Benetti S, 2021: Deaf & Hearing: Radial > Horizontal
// Benetti S, 2021: Deaf > Hearing: Radial > Horizontal
// Subjects=13
-48	-73	8
-30	-70	-7
54	-70	8
36	-67	2
-27	-55	53
30	-52	50
45	11	32
-39	-64	2
45	-64	2
30	20	8
-42	-34	47
60	-37	11
48	-34	50
54	-22	-1
60	-34	11
-42	-70	2
-42	-70	-1
48	-61	-10
48	-55	-13
-33	-61	-13
69	-19	-1
27	38	38
-66	-37	14

// Simon M, 2020: Deaf
// Subjects=16
-54	2	43
-39	-43	-20
30	-46	49
-12	-16	7
6	-22	-11
36	-4	-41
66	-28	7
-54	-34	10
-57	-1	43
18	17	4
-33	-58	7
-3	-61	-32
57	8	37
66	-25	4
-60	-31	7
-54	2	43
18	17	4
66	-28	7
-51	-37	10
66	-28	7
-63	-31	7
-57	-1	46

// Simon M, 2020: Hearing
// Subjects=16
39	-43	-20
-51	-70	1
30	26	1
-12	-73	-44
-9	-16	4
27	-49	49
66	-28	7
-54	-34	10
-57	-1	43
18	17	4
-33	-58	7
-3	-61	-32
57	8	37
66	-25	4
-60	-31	7
-54	2	43
18	17	4
66	-28	7
-51	-37	10

// Miranda-Olivos R, 2021: Now > Later: Binge Eating Disorder (BED) & Non-BED 
// > Healthy Controls
// Subjects=10
-50	4	10

// Gool J K, 2020: Task > Baseline, All Subjects
// Gool J K, 2020: Difficult > Baseline, Controls > Patients
// Gool J K, 2020: Error-related Activations, Controls > Patients
// Subjects=11
22	-62	-22
48	16	-10
4	2	52
-28	-74	-20
-38	-18	52
-12	-6	12
30	-86	4
36	-68	-12
64	-44	16
34	6	-8
-34	-4	-10
26	54	18
-22	2	4
-40	20	-8
-32	-18	0
-28	-54	52
44	-82	-10
-2	-74	0
54	14	-4
0	24	52
46	14	34
52	-50	-26
-54	16	-4
-42	-16	50
-60	-60	8
-44	10	40
6	-16	12
-62	-36	2
-46	-70	-12
54	-56	32
-24	-92	16
-30	62	16
0	24	52
-42	-4	36

// Grothe M, 2020: Multiple Sclerosis (MS)
// Subjects=20
-18	-90	-6
-21	-63	48
21	-87	-3
-3	6	57
9	12	51
-45	-9	42
48	-6	33
-24	-3	51
-30	0	66
30	0	57

// Grothe M, 2020: Healthy Controls (HC)
// Subjects=20
-18	-63	57
-24	-63	48
21	-66	51
-45	-9	-42
-33	0	63
-24	-3	51
48	-6	36
-3	6	60
33	0	60
9	15	39
48	-27	3

// Lewis C E, 2021: Fetal Alcohol Syndrome (FAS)
// Subjects=11
-22	-66	54
-22	-60	46
20	-64	52
44	-78	26
32	-82	26
32	-86	10
52	-62	-12
42	-62	-8
-42	-84	24
-48	-60	-8
-48	-52	-14
-48	-72	-4
52	-52	-10
-30	-84	28
-20	-36	-12
-26	-30	-20
-30	-40	-14
32	-38	-12
24	-36	-14
34	-48	-18
18	-34	-2
-14	-32	68
-2	-36	64
4	-40	52
-14	-32	68
-22	-28	66
-28	-28	54
-12	-38	52
-2	-42	48
40	-64	20
36	-54	24

// Lewis C E, 2021: Heavily Exposed Non-syndromal (HE)
// Subjects=14
-22	-66	54
-22	-60	46
20	-64	52
44	-78	26
32	-82	26
32	-86	10
52	-62	-12
42	-62	-8
-42	-84	24
-48	-60	-8
-48	-52	-14
-48	-72	-4
52	-52	-10
-30	-84	28
-20	-36	-12
-26	-30	-20
-30	-40	-14
32	-38	-12
24	-36	-14
34	-48	-18
18	-34	-2
-14	-32	68
-22	-28	66
-28	-28	54
-12	-38	52
-2	-42	48
40	-64	20
36	-54	24

// Lewis C E, 2021: Healthy Controls (HC)
// Subjects=26
-22	-66	54
-22	-60	46
20	-64	52
44	-78	26
32	-82	26
32	-86	10
52	-62	-12
42	-62	-8
-42	-84	24
-48	-60	-8
-48	-52	-14
-48	-72	-4
52	-52	-10
-30	-84	28
-20	-36	-12
-26	-30	-20
-30	-40	-14
32	-38	-12
24	-36	-14
34	-48	-18
18	-34	-2
-14	-32	68
-2	-36	64
4	-40	52

// Baumann S, 2021: Attention Deficit Hyperactivity Disorder (ADHD)
// Subjects=19
30	-10	-6
24	0	0
28	6	-6
40	22	-8

// Baumann S, 2021: Conduct Disorder and Attention Deficit Hyperactivity 
// Disorder (CD + ADHD)
// Subjects=45
10	12	8
14	2	12
10	4	4
-42	14	36
-52	18	22
-44	-60	54
30	-10	-6
24	0	0
28	6	-6
40	22	-8

// Baumann S, 2021: Healthy Controls (HC)
// Subjects=61
10	12	8
14	2	12
10	4	4
-42	14	36
-52	18	22
-44	-60	54

// Bitan T, 2020: Developmental dyslexia
// Subjects=21
-40	-78	-12
56	-26	12
-8	56	-4
-4	14	52
-30	36	-10
36	38	-8
14	14	38
-44	-40	42
-26	-76	22
-20	28	48
8	8	-8
-14	52	40
0	60	30
0	60	30

// Bitan T, 2020: Healthy controls
// Subjects=22
-58	-12	26
-32	-88	-4
62	-6	12
-36	34	-12
34	-92	-8
52	-70	26
24	22	48

// Menks W M, 2021: Emotional Face Processing: Healthy Controls (HC) > Conduct 
// Disorder (CD)
// Menks W M, 2021: Emotional Face Processing: HC > CD, corrected for eye gaze 
// behavior
// Menks W M, 2021: Emotional Face Processing: HC (matched) > CD (matched)
// Menks W M, 2021: Emotional Face Processing: HC (matched) > CD (matched), 
// corrected for eye gaze behavior
// Subjects=18
58	-20	18
22	-48	-2
-22	-48	-2
-50	-76	0
-16	-50	0
44	-30	58
22	-48	-2
-50	-76	0
14	-90	-6
-14	-90	-6
-10	-58	-4
56	-18	18
24	-48	-2
40	-40	64
-48	-78	0
34	-86	6
-34	-36	66
-54	-24	-14
16	-86	-12
24	-48	-2
-18	-48	0
-16	-72	32
-48	-78	0

// Carvalho G F, 2021: Main effect of Roller Coaster Ride, Migraine
// Carvalho G F, 2021: Healthy Controls > Migraine
// Carvalho G F, 2021: Migraine > Healthy Controls
// Carvalho G F, 2021: Migraine without aura > Migraine with aura
// Subjects=10
5	-82	-2
-11	-19	43
37	-30	20
46	5	35
-37	-32	20
27	-4	51
-27	-7	52
-52	5	38
-16	-7	1
30	-27	-28
19	15	-23
21	6	-31
28	26	-4
57	-35	22
24	16	6
-23	-25	-27
4	-4	41
-34	53	-4
-32	-66	-45
28	-90	10
-37	-71	-6
-5	-27	-38
-25	-41	-30
24	-76	9
11	-14	51
25	39	-16
51	40	-12
57	-29	24
48	-31	5
-30	-30	61
60	-11	-1
-53	-38	31
54	-62	-35

// Soloveva M V, 2020: Stop > Go, All Participants
// Soloveva M V, 2020: Stop > Go, Pre-Huntington's Disease > Healthy Controls
// Subjects=15
56	-14	6
-48	-24	4
-58	-44	6
60	-36	6
60	-44	24
-56	-48	28
16	-62	12
-14	-66	10
54	-40	54
-58	-44	38
-34	16	0
32	20	-10
-6	-64	4
24	-54	0
-6	-46	52
10	-44	50
-42	14	30
52	24	30
-58	-60	24
52	-52	32
12	-78	38
-10	-80	38
-40	12	30
46	10	30
-42	12	30
44	8	30
-8	16	44
6	2	54
42	10	58
-32	-2	52
14	-82	48
-28	-66	52
-22	4	66
18	16	60
10	-4	44
-4	-10	44
18	-80	36
-10	-80	42
18	14	-4
-18	4	-8
-42	-78	12
30	-72	30
-14	6	12
12	14	4
24	-10	-32
2	-22	-26
20	-26	0
-18	-48	70
60	-26	36
-8	20	30
-4	-14	62
2	-52	-38
-8	-78	4
18	-74	4

// Trimmel K, 2021: Left Temporal Lobe Epilepsy (LTLE)
// Subjects=41
-46	30	14
-10	50	48
-4	18	54
-48	-52	-18
-52	-34	-4
-42	24	-18
-20	-20	-22
-6	-56	0
-24	-80	34
20	-18	18
-48	-64	40
-62	-48	38
-62	-56	18
-30	48	-2
-46	-38	12
4	-74	38
34	-74	54
30	18	62
18	62	16
32	-10	52
58	-62	-14
-44	8	28
-4	16	54
-34	-46	-24
-42	-74	-8
-36	-88	-4
42	-84	-4
-56	-68	24
-48	-18	2
-54	2	-32
2	-68	42
44	-78	40
30	24	60
-16	14	24
-2	10	64
-54	0	44
-26	-70	40
-36	-66	-26
44	16	-6
26	-100	10
36	-66	-28
-44	-56	36
-10	-48	34
-56	-66	32
-50	10	-36
-46	6	-44
-28	-34	-20
-44	-16	10
-40	-88	22
4	-64	32
6	-52	32
24	36	42
2	58	-2
52	-26	20
52	-68	18
24	-18	-30
34	4	10
44	-76	34
-46	-56	-14
32	-66	-26
40	36	38
-34	-50	-14
28	12	50
-38	12	44
-34	10	-32
-54	-12	-22
-34	36	6
-66	-26	26
6	-82	42
-54	-12	-22
-34	36	4
-54	22	32
-66	-26	26
6	-82	52
52	-50	8
-48	30	6
-58	0	-18
-44	8	-26
-38	30	-20
-40	10	-44
4	-54	48
-44	-56	34
-42	-30	36
-52	-42	58
-52	-22	24
-36	-46	-16
-30	-98	10
-48	-74	-10
-40	-60	-14
-4	-66	52
4	-64	60
32	-52	36
-38	-46	-18
-46	-84	-8
-34	-10	-28
-48	30	4
-36	40	-14
-44	12	-20
-38	30	-20
-42	8	-44
-34	8	-36
4	-54	48
-46	-68	-4
-36	-54	-8
-30	-98	12
-40	-42	-14
-4	-66	52
32	-52	36

// Trimmel K, 2021: Right Temporal Lobe Epilepsy (RTLE)
// Subjects=31
-46	30	14
-10	50	48
-4	18	54
-48	-52	-18
-52	-34	-4
-42	24	-18
-20	-20	-22
-6	-56	0
-24	-80	34
20	-18	18
-48	-64	40
-62	-48	38
-62	-56	18
-30	48	-2
-46	-38	12
4	-74	38
34	-74	54
30	18	62
18	62	16
32	-10	52
58	-62	-14
-44	8	28
-4	16	54
-34	-46	-24
-42	-74	-8
-36	-88	-4
42	-84	-4
-56	-68	24
-48	-18	2
-54	2	-32
2	-68	42
44	-78	40
30	24	60
-16	14	24
-2	10	64
-54	0	44
-26	-70	40
-36	-66	-26
44	16	-6
26	-100	10
36	-66	-28
-44	-56	36
-10	-48	34
-56	-66	32
-50	10	-36
-46	6	-44
-28	-34	-20
-44	-16	10
-40	-88	22
4	-64	32
6	-52	32
24	36	42
2	58	-2
52	-26	20
52	-68	18
24	-18	-30
34	4	10
44	-76	34
-46	-56	-14
32	-66	-26
40	36	38
-34	-50	-14
28	12	50
-38	12	44
-34	10	-32
-54	-12	-22
-34	36	6
-66	-26	26
6	-82	42
-54	-12	-22
-34	36	4
-54	22	32
-66	-26	26
6	-82	52
52	-50	8
-38	30	-20
-40	10	-44
-52	-42	58
-52	-22	24
-48	-74	-10
-40	-60	-14
-34	-10	-28
-38	30	-20
-42	8	-44
-34	8	-36
-40	-42	-14
32	-52	36

// Trimmel K, 2021: Healthy Controls (HC)
// Subjects=36
-46	30	14
-10	50	48
-4	18	54
-48	-52	-18
-52	-34	-4
-42	24	-18
-20	-20	-22
-6	-56	0
-24	-80	34
20	-18	18
-48	-64	40
-62	-48	38
-62	-56	18
-30	48	-2
-46	-38	12
4	-74	38
34	-74	54
30	18	62
18	62	16
32	-10	52
58	-62	-14
-44	8	28
-4	16	54
-34	-46	-24
-42	-74	-8
-36	-88	-4
42	-84	-4
-56	-68	24
-48	-18	2
-54	2	-32
2	-68	42
44	-78	40
30	24	60
-16	14	24
-2	10	64
-54	0	44
-26	-70	40
-36	-66	-26
44	16	-6
26	-100	10
36	-66	-28
-44	-56	36
-10	-48	34
-56	-66	32
-50	10	-36
-46	6	-44
-28	-34	-20
-44	-16	10
-40	-88	22
4	-64	32
6	-52	32
24	36	42
2	58	-2
52	-26	20
52	-68	18
24	-18	-30
34	4	10
44	-76	34
-46	-56	-14
32	-66	-26
40	36	38
-34	-50	-14
28	12	50
-38	12	44

// Caseras X, 2022: Chronic Fatigue Syndrome (CFS)
// Subjects=17
31.94	57.2	1.92
5.93	-69.74	41.86
40.11	-57.56	44.91
55.53	21.84	-3.19
51.19	24.48	-10.05
25.15	-74.11	38.66
43.78	49.32	9.14
5.14	63.84	-6.13
-14.07	51.83	-8.25
5.24	69.18	7.91
8.46	57.31	5.53
-6.51	52.74	2.74
31.9	61.17	-1.76
-30.11	60.45	-5.45
-13.98	33.06	-3.33
55.71	-49.86	-8.33
31.9	61.17	-1.76
-34.38	60.43	-5.39
-17.58	-78.6	39.53
20.95	-69.05	49.44
58.79	-39.07	-20.43

// Caseras X, 2022: Healthy Controls
// Subjects=12
-2.59	-69.45	46.39
43.87	42.52	17.51
8.75	-85.81	-14.82
47.24	27.79	33.21
1.64	-74.25	38.94
32.53	13.81	60.2
35.22	62.3	12.61
5.6	27.88	38.14
44.3	-50.73	36.48
55.64	30.7	15.02
31.9	61.17	-1.76
-34.38	60.43	-5.39
-17.58	-78.6	39.53
20.95	-69.05	49.44
58.79	-39.07	-20.43

// Damestrani N L, 2021: Deviant+Novel>Silent; GRE-EPI Session 1
// Damestrani N L, 2021: Deviant+Novel>Silent; GRE-EPI Session 2
// Damestrani N L, 2021: Deviant+Novel>Silent; Looping Star Session 1
// Damestrani N L, 2021: Deviant+Novel>Silent; Looping Star Session 2
// Damestrani N L, 2021: Deviant>All; GRE-EPI Session 1
// Damestrani N L, 2021: Deviant>All; GRE-EPI Session 2
// Damestrani N L, 2021: Deviant>All; Looping Star Session 1
// Damestrani N L, 2021: Deviant>All; Looping Star Session 2
// Damestrani N L, 2021: Novel>All; GRE-EPI Session 1
// Damestrani N L, 2021: Novel >All; GRE-EPI Session 2
// Damestrani N L, 2021: Novel>All; Looping Star Session 1
// Damestrani N L, 2021: Novel>All; Looping Star Session 2
// Damestrani N L, 2021: Novel> Deviant; GRE-EPI Session 1
// Damestrani N L, 2021: Novel> Deviant; GRE-EPI Session 2
// Damestrani N L, 2021: Novel> Deviant; Looping Star Session 1
// Damestrani N L, 2021: Novel> Deviant; Looping Star Session 2
// Damestrani N L, 2021: Deviant> Novel; GRE-EPI Session 1
// Damestrani N L, 2021: Deviant> Novel; Looping Star Session 1
// Damestrani N L, 2021: Deviant> Novel; Looping Star Session 2
// Damestrani N L, 2021: Deviant+Novel>All; GRE-EPI Session 1
// Damestrani N L, 2021: Deviant+Novel>All; GRE-EPI Session 2
// Damestrani N L, 2021: Deviant+Novel>All; Looping Star Session 1
// Damestrani N L, 2021: Deviant+Novel>All; Looping Star Session 2
// Subjects=12
-46	-28	10
66	-20	10
42	-32	46
34	28	26
58	-20	18
-62	-20	18
-6	0	58
6	-84	-10
-14	24	6
50	-32	14
2	-76	-22
34	-52	-26
-2	4	50
-34	-4	58
-46	6	-6
-58	-20	22
6	-64	-14
62	-12	6
50	16	-10
2	4	66
-50	-28	10
34	8	34
54	8	-2
62	-16	18
10	-92	-6
-58	-16	50
2	12	58
-62	-20	22
10	28	-2
-2	0	66
-50	-24	10
-54	4	-2
54	-20	22
30	0	-6
2	-76	-22
-50	-20	42
-6	-40	-22
-6	-80	10
-58	-20	18
-10	-48	-2
-42	-36	-10
-34	36	26
30	32	26
-46	-20	58
-58	-24	14
-2	0	62
62	-20	18
54	-32	14
-2	-72	-18
-2	0	66
-43	4	-6
-62	-20	10
-14	-20	2
-18	-28	78
-54	-24	42
58	-16	6
14	-44	-14
54	12	-6
54	-24	30
-46	12	18
22	-84	26
-18	-92	26
-18	-8	22
-46	-40	10
58	-32	15
42	-44	14
14	-64	46
22	12	14
-38	-36	-6
-50	-28	10
54	12	-2
30	-4	18
2	12	58
62	-20	18
-46	-20	58
2	-84	-10
-6	28	2
-62	-20	18
-2	0	66
50	-32	14
2	-76	-22
-62	-20	6
-54	8	-6
-50	-20	42
-6	-80	10
50	16	-10
-46	12	18
-6	-40	-22

// Di X, 2020: 2-back > 1-back
// Di X, 2020: 2-back < 1-back
// Subjects=49
24	11	56
-24	8	50
-48	5	32
-6	-61	44
-18	-70	50
21	-67	53
48	5	23
27	-61	-37
9	-73	-31
-18	5	11
-30	26	2
-33	50	2
-42	50	2
-3	-16	32
0	-37	20
0	-28	44
39	-19	20
36	-16	2
39	2	-1
12	59	20
-6	62	8
-9	53	-1
-36	-10	-4
-63	-25	5
-39	-19	17
21	38	-1

// Li G, 2021: 2-back > 0-back, positive correlation with Critical Success 
// Index (CSI)
// Li G, 2021: 2-back > 0-back, negative correlation with CSI
// Li G, 2021: 2-back > 0-back, positive correlation with reaction time (RT)
// Li G, 2021: 2-back > 0-back, negative correlation with RT
// Li G, 2021: 2-back > 0-back, positive correlation with Ravens Standard 
// Progressive Matrices (PMAT24_A_CR)
// Li G, 2021: 2-back > 0-back
// Li G, 2021: 2-back < 0-back
// Subjects=949
-2	-2	46
4	26	46
-42	8	42
44	-54	40
34	18	2
-36	-54	42
-6	16	48
-35	-54	42
-16	0	20
52	-28	26
-2	-6	46
-2	-52	26
-38	-16	20
-10	48	40
38	-20	46
-44	-14	34
44	-46	44
-45	-38	44
-2	10	48
30	8	54
-28	-58	48
-22	10	60
-4	-62	48
34	28	2
24	6	58
42	-44	48
2	-28	-2
-2	12	24
-2	-44	-16
-18	-38	14
-2	-48	30
-12	52	36
8	52	38
0	-14	6

// Schmidt C, 2020: Incongruent > Congruent (right hand > left hand)
// Schmidt C, 2020: Incongruent > Congruent (left hand > right hand)
// Schmidt C, 2020: Incongruent > Congruent (right visual field > left visual 
// field)
// Schmidt C, 2020: Incongruent > Congruent (left visual field > right visual 
// field)
// Schmidt C, 2020: Incongruent > Congruent
// Subjects=13
-48	-20	60
16	-48	-20
42	-14	68
-20	-48	-28
46	-14	14
-10	-92	0
14	-92	6
16	26	32
20	24	6
-12	18	14
50	-16	12

// Talanow T, 2020: go/no-go task
// Subjects=19
12	-86	-8
4	-92	-8
16	-88	0
-16	-80	-10
-14	-98	6
-8	-80	-8
50	44	10
34	38	14
12	54	28
-10	48	30
-16	30	48
-54	-38	34
-58	-26	42
-64	-30	34
26	-96	14
40	-80	24
12	-92	28
56	-34	40
68	-26	30
66	-40	32
4	-92	-8
-16	-80	-10
-6	-92	-12
-58	-26	42
-52	-30	54
-64	-20	32
58	-52	44
64	-50	30
52	-60	46
0	-92	0
8	-76	-10
-4	-96	10
-10	-74	-10
16	-96	2
2	-88	18
-2	-78	22
20	-100	14
-2	-85	36
0	-86	30
2	-72	14
0	-68	14
10	-84	38
-10	-62	6
0	-56	4
-22	-88	12

// Talanow T, 2020: prosaccade/antisaccade task
// Subjects=21
-56	-16	12
-62	-20	18
-14	-94	22
16	-92	24
26	-90	22
-56	-16	10
-40	-36	14
-48	-20	36
64	-22	12
66	-32	8
10	28	44
24	28	34
30	28	28
20	44	28
-14	50	28
-20	34	42
48	2	36
46	-8	36
50	22	16

// Weigard A, 2020: No-go (successful inhibitions) > Go
// Weigard A, 2020: No-go (failed inhibitions) > Go
// Weigard A, 2020: Positive relation between No-go (failed inhibitions) > Go 
// and mean of drift rates on go & no-go trials
// Subjects=143
58	-44	28
40	42	22
34	20	0
-58	-48	34
-62	-50	24
-62	-44	12
-34	38	26
-34	46	24
-40	38	40
-22	58	-14
8	-10	28
4	-22	24
-10	-22	30
-36	-20	50
-32	-12	56
-44	-26	48
12	20	-22
4	30	26
44	14	-4
-28	50	22
-44	14	-6
-32	18	-12
-60	-42	30
60	-42	26
52	-30	-8
54	-40	-2
-32	-60	-28
-30	-48	-32
38	-52	-32
2	-72	-20
2	-60	-8
46	2	-40
12	-68	36
-12	-68	32
12	-76	8
-6	-74	6
10	-36	-34
-10	-48	-32
26	54	-16
50	24	0
32	24	-10
34	16	-6
8	38	18
4	48	8
-10	34	14
-10	40	2
62	-30	-8
58	-16	-10

// Narayana S, 2020: Typical Speakers
// Subjects=19
-50	-10	40
-52	-8	34
-52	4	4
-12	-12	60
0	0	62
10	12	42
56	-6	38
52	-4	38
52	14	4
8	12	-20
-62	-30	2
-56	-18	10
52	-36	12
68	-22	6
62	-6	0
46	-24	10
-56	-4	16
-24	-62	52
60	-6	20
18	-42	52
-32	-38	18
-40	10	6
-30	8	12
44	6	6
-12	-96	8
-2	90	0
4	-84	-2
-22	-58	-26
-8	-68	-44
18	-64	-16
12	-40	-30
10	-70	-42
-56	-6	42
-52	-10	28
-52	2	48
-2	6	42
-16	10	34
6	6	64
54	-8	32
56	-2	42
58	-4	8
-64	-18	-2
-56	-42	6
50	-30	2
66	-26	2
-58	-4	16
56	-6	18
-28	22	12
22	14	12
-2	-96	-2
-6	-84	-2
8	-80	0
10	-98	2
-22	-62	-22
-12	-62	-18
-8	-72	-38
16	-66	-22
26	-56	-26
12	-70	-40
-52	-8	34
-12	-12	60
60	-6	20
-46	-34	18
-54	-24	18
-22	-56	-22
-42	-56	48
-54	-4	38
-40	-16	34
-58	-8	16
-40	-58	52
-46	-70	38

// Narayana S, 2020: Parkinson's Disease (PD) with Hypokinetic Dysarthria 
// (HKD), PET study
// Subjects=10
-46	-14	42
-62	0	22
-46	-2	48
-6	0	68
-4	16	50
-10	20	32
-48	6	8
50	-2	38
2	6	60
-54	12	-8
-48	-32	-4
24	-70	54
-40	18	8
-2	-86	-4
-22	-96	-8
-26	92	2
-48	-66	-14
2	-86	0
22	-96	0
-16	-72	-20
-30	-50	-24
-24	-70	-40
12	-68	-18
28	-62	-24
12	-76	-40
-52	-8	34
-12	-12	60
60	-6	20
-46	-34	18
-54	-24	18
-22	-56	-22
-42	-56	48

// Narayana S, 2020: Parkinson's Disease (PD) with Hypokinetic Dysarthria 
// (HKD), fMRI study
// Subjects=21
-52	-8	48
-58	-6	20
-46	4	48
-10	4	66
-2	12	66
-10	14	40
50	-8	42
60	-4	30
52	14	6
6	12	52
44	16	26
50	4	44
8	20	42
-62	-14	4
-54	-24	-2
56	-18	6
58	-26	0
52	-24	-6
-30	-58	50
28	-66	42
-12	-16	4
12	-14	4
-6	-84	-12
-16	-102	2
18	-100	2
6	-80	0
14	-94	-12
-28	-64	-22
26	-64	-24
36	-74	-22
-54	-4	38
-40	-16	34
-58	-8	16
-40	-58	52
-46	-70	38

// Allen M D, 2022: Faces > Rest, Unmedicated
// Allen M D, 2022: Faces > Rest, Medicated
// Subjects=1
28	-21	-21
-33	-18	-20
-24	-2	-18
48	17	41
36	48	17
15	26	60
47	24	32
50	-4	45
39	-18	59
-47	13	48
-17	46	48
-18	4	72
-46	21	19
-55	1	41
35	-76	-4
26	-62	-14
21	-98	-11
33	-95	1
-35	-57	-19
-31	-84	-16
-16	-89	-17
-38	-77	-17
-18	-100	-10
-43	-84	-3
33	-51	64
-49	-46	56
39	-22	-16
-29	-17	-21
0	17	49
40	3	53
41	30	38
51	16	25
45	5	26
-48	15	49
-32	5	63
-49	30	38
-15	10	68
-52	23	30
-51	10	41
28	-71	-8
35	-77	-15
17	-97	-10
25	-90	-13
36	-89	-10
42	-85	10
-33	-58	-13
-24	-89	-12
-31	-68	-8
-36	-83	11
23	-67	63
33	-50	43
-25	-71	43

// Araneda R, 2022: Right hand + Left hand + Both hands > Rest
// Araneda R, 2022: Right hand > Rest, post HABIT-ILE > pre HABIT-ILE
// Araneda R, 2022: Left hand > Rest, post HABIT-ILE > pre HABIT-ILE
// Araneda R, 2022: Both hands > Rest, post HABIT-ILE > pre HABIT-ILE
// Subjects=25
1.45	3.97	45.77
1.52	2.45	53.7
57.04	-5.39	43.68
49.72	-23.53	57.55
43.32	-30.08	55.95
34.78	-6.9	67.48
60.19	-3.77	36.82
62.01	10.59	2.14
61.13	-18.25	14.6
44.91	-2.8	-4.35
14.03	-18.25	5.11
16.1	-55.18	-18.58
-36.85	-17.61	59.17
-32.55	-23.93	59.65
-21.32	-52.32	-19.51
-30.41	-15.03	64.45
-35.72	-33.47	60.49
1.46	4.05	46.87
1.51	4.57	53.52
55.98	-5.31	44.8
50.8	-23.43	58.65
43.39	-43.57	60.42
33.72	-6.9	67.5
62.17	10.02	22.26
58.78	12.52	-.22
14.03	-18.25	5.11
13.97	-55.2	-18.56
45.98	3.81	-1.57
-35.77	-13.12	62.13
-40.02	-20.55	62.8
-21.32	-52.32	-19.51
-34.65	-35.58	60.65
-30.43	-5.43	64.76
1.46	4.05	46.87
1.57	-4.69	57.64
36.91	-7.06	65.24
55.98	-8.57	43.96
46.53	-25.57	58.88
66.53	-19.82	21.36
-44.33	-17.66	59.26
-33.6	-23.68	62.99
-18.1	-52.22	-18.44
1.45	3.97	45.77
1.52	2.45	53.7
1.46	4.05	46.87
1.51	4.57	53.52
1.46	4.05	46.87
1.57	-4.69	57.64
-37.02	13.59	49.86
-56.36	2.51	32.06
-18.21	45.52	6.82
-11.52	-43.78	7.54
-11.3	-54.67	31.87
60.11	-2.43	26.67
49.28	-1.75	8.9
23.75	45.42	43.15
-2.05	50.33	26.31
4.37	50.37	26.23
1.71	-42.76	60.83
40.1	-19.27	58.42
47.56	-27.05	53.41
60.11	3.12	29.55
33.29	24.91	24.69
20.45	-5	10.61
13.93	3.7	-0.08
46.09	-4.85	10.31
36.86	-66.81	35.68
11.12	-54.79	28.28
-21.39	45.76	10.18
-41.21	-64.62	29.7
-11.3	-54.67	31.87
23.7	31.71	30.92
17.1	46.25	13.05
33.76	-72.4	46.22
20.73	-44.96	30.69
13.94	0.53	0.19
30.08	-71.76	-14.01
-49.8	-2.51	49.13
-17.97	28.29	31.68
-50.21	29.47	8.54
-34.2	49.11	13.4
-17.58	-33.62	56.94
-46.72	-59.85	9.29
-20.89	-47.87	38.1
-14.75	-30.85	9.84

// Kesler S R, 2022: Turner Syndrome
// Subjects=13
38.2	-79.48	11.59
-43.96	-82.31	8.79
36.55	-41.74	59.43
46.93	-29.51	28.91
40.54	-34.33	35.1
-24.3	3.6	42.54
3.61	31.9	33.66
3.73	-29.56	30.77
0.76	58.48	-14.87
-56.33	-21.47	-17.19

// Kesler S R, 2022: Healthy Controls
// Subjects=13
-46.12	-81.25	8.72
25.85	-64.01	62.94
40.68	-39.88	44.61
48.72	-73.86	-9.31
-41.74	-81.89	13.19
34.46	-68.54	59.88
6.07	14.42	53.27
-24.27	3.81	44.76
46.93	-29.51	28.91
40.54	-34.33	35.1
-24.3	3.6	42.54
3.61	31.9	33.66
3.73	-29.56	30.77
0.76	58.48	-14.87
-56.33	-21.47	-17.19

// Donnelly B, 2022: Healthy Controls (HC) > Binge Eating Group (BEG): Low 
// energy disgust > Neutral
// Donnelly B, 2022: BEG > HC: Low energy fear > Neutral
// Donnelly B, 2022: HC > BEG: Low energy fear > Neutral
// Donnelly B, 2022: BEG > HC: Low energy happy > Neutral
// Donnelly B, 2022: HC > BEG: High energy disgust > Neutral
// Donnelly B, 2022: HC > BEG: High energy fear > Neutral
// Donnelly B, 2022: HC > BEG: High energy happy > Neutral
// Subjects=19
20	-36	-22
-34	-68	-8
8	-65	-10
38	-2	30
10	-88	22
-44	40	-6
-16	-6	48
-10	-42	68
38	-12	-22
-30	-70	6
14	-46	-8
46	-22	24
38	-70	10
-34	-32	-26
4	4	64
32	50	26
-22	-82	-38
50	22	-2
-28	-68	28
10	-58	4
0	-4	-12
-12	-60	-2
-40	-71	10
42	4	-34
10	2	66
48	36	-8
-2	2	-6

// Schneider E, 2022: Placebo > LDX, Food > Non-food
// Schneider E, 2022: Food > Non-food
// Subjects=22
10	-8	3
-35	-48	-10
-10	-10	8
30	30	3
-37.5	-5	7.5
-35	35	20
-5	-50	17.5
-30	32.5	-5
-47.5	-47.5	-20
-25	-65	37.5
37.5	0	7.5
-15	30	52.5
-2.5	-10	7.5
-2.5	0	32.5
-47.5	10	35
-45	-65	37.5
17.5	40	42.5
37.5	37.5	17.5

// Bhikram T, 2021: Tourette Syndrome
// Subjects=39
48	-34	22
15	-37	41
-12	38	43
15	-7	58
-6	-22	16
32	-37	-2
15	-9	24
-45	-50	19
27	-46	4
-4	-41	37
-39	5	-2
-34	-3	15
-7	-5	0
-30	32	7
-39	-16	16
39	41	-5
3	-52	-47
-36	-25	-11
-6	-34	58
15	-22	52
-44	-37	28
39	-16	49
-48	-55	1
-51	-40	28
39	-30	40
12	23	49
-48	-8	40
48	-12	40
33	23	34
-18	-67	-11
30	-16	7
-6	-1	46
36	20	1
-60	-7	1

// Bhikram T, 2021: Healthy Controls (HC)
// Subjects=20
48	-34	22
15	-37	41

// Gool J K, 2022: All Participants: Active sleep resistance > Waking rest
// Gool J K, 2022: All Participants: Waking rest > Active sleep resistance
// Subjects=12
-20	-30	-2
56	-44	-4
36	-68	42
44	32	18
-48	-54	-6
56	-66	0
42	-18	-30

// Openneer T J C, 2021: Tourette Syndrome without ADHD
// Subjects=28
-44	-44	12
-44	-46	12

// Openneer T J C, 2021: Tourette Syndrome with ADHD
// Subjects=23
-44	-44	12
-44	-46	12
52	-4	-18
38	32	-10
-40	-18	-8
56	8	-14

// Openneer T J C, 2021: Healthy Controls
// Subjects=52
52	-4	-18
38	32	-10
-40	-18	-8
56	8	-14

// Zapparoli L, 2020: Healthy Controls
// Subjects=25
-26	-24	58
-28	-24	64
-26	-22	68
-40	-22	56
-12	-54	-14
-20	-52	-20
-14	-58	-16
-22	-56	-18
-26	-54	-20
-50	14	0
-52	18	22
-46	8	26
-46	4	28
-42	36	20
-46	28	20
-52	22	20
-36	44	14
-42	34	8
-36	52	16
-2	2	50
-14	-68	48
-24	-64	38
-20	-62	48
-22	-68	46
-48	10	-2
-34	-66	-12
-24	-64	30
-40	-80	4
-32	-90	16
-36	-68	-8
-2	-72	6
-10	-84	12
-22	-68	-18
44	8	14
44	12	16
44	10	22
52	10	32
40	12	12
38	38	30
30	52	20
36	4	60
36	-4	62
36	-4	62
38	-16	64
42	-10	58
48	-8	50
4	0	58
32	-20	48
32	-16	44
36	-14	42
40	-16	54
46	-28	42
38	-20	46
36	-20	50
42	-24	44
38	24	0
40	20	0
38	14	4
46	12	0
46	-32	44
48	-38	44
52	-40	42
24	-82	32
30	-88	6
28	-70	34
32	-80	-6
36	-64	-24
32	-42	-28
-2	-14	54
-34	-22	60
-32	-82	16
-40	-78	0
-18	-56	-16
38	44	24
0	12	44
8	12	40
0	-10	52
24	-66	48
30	-88	6
28	-52	-20
4	-70	-14
-58	-26	22
-58	-30	24
-58	-46	10
48	-60	14
52	-60	12
54	-60	24
52	-66	24
-46	-28	20
-46	-64	14
-48	-60	14
52	-28	24
-48	24	2
-44	28	4
-54	22	0
-18	4	64
-14	10	54
-28	-12	62
-26	-8	66
-16	8	64
-4	18	62
-8	10	54
-6	14	54
-4	18	56
-40	-20	58
-38	-18	62
-40	12	2
-40	4	-8
-42	6	-4
-20	-30	-4
-18	-34	-6
-14	-44	-10
-2	-38	-10
-20	-2	-4
-22	-8	0
-24	-16	-2
-18	-8	2
10	44	44
58	22	-2
60	16	0
14	26	48
14	22	50
18	32	48
38	-38	62
34	-40	64
52	-30	50
32	-40	68
36	-42	60
40	22	-6
46	14	-4
22	-34	-10
10	-46	-6
10	-44	-10
12	-40	-10
16	-10	-2
8	-4	-6

// Zapparoli L, 2020: Gilles de la Tourette Syndrome
// Subjects=25
-26	-24	58
-28	-24	64
-26	-22	68
-40	-22	56
-12	-54	-14
-20	-52	-20
-14	-58	-16
-22	-56	-18
-26	-54	-20
-50	14	0
-52	18	22
-46	8	26
-46	4	28
-42	36	20
-46	28	20
-52	22	20
-36	44	14
-42	34	8
-36	52	16
-2	2	50
-14	-68	48
-24	-64	38
-20	-62	48
-22	-68	46
-48	10	-2
-34	-66	-12
-24	-64	30
-40	-80	4
-32	-90	16
-36	-68	-8
-2	-72	6
-10	-84	12
-22	-68	-18
44	8	14
44	12	16
44	10	22
52	10	32
40	12	12
38	38	30
30	52	20
36	4	60
36	-4	62
36	-4	62
38	-16	64
42	-10	58
48	-8	50
4	0	58
32	-20	48
32	-16	44
36	-14	42
40	-16	54
46	-28	42
38	-20	46
36	-20	50
42	-24	44
38	24	0
40	20	0
38	14	4
46	12	0
46	-32	44
48	-38	44
52	-40	42
24	-82	32
30	-88	6
28	-70	34
32	-80	-6
36	-64	-24
32	-42	-28
-2	-14	54
-34	-22	60
-32	-82	16
-40	-78	0
-18	-56	-16
38	44	24
0	12	44
8	12	40
0	-10	52
24	-66	48
30	-88	6
28	-52	-20
4	-70	-14
-58	-26	22
-58	-30	24
-58	-46	10
48	-60	14
52	-60	12
54	-60	24
52	-66	24
-46	-28	20
-46	-64	14
-48	-60	14
52	-28	24

// Udd¨¦n J, 2022: Healthy Controls: Visual
// Subjects=102
-52	-30	-4
-56	2	-16
-50	-36	-2
-54	8	-18
-48	28	0
-56	18	14
-50	-54	16
-54	-56	18
-52	-54	12
48	-16	8
44	-24	10
-38	30	12

// Udd¨¦n J, 2022: Healthy Controls: Auditory
// Subjects=102
-52	-30	-4
-56	2	-16
-50	-36	-2
-54	8	-18
-48	28	0
-56	18	14
-50	-54	16
-54	-56	18
-52	-54	12
48	-16	8
44	-24	10
-38	30	12
-38	-30	12
-48	-20	8
50	-16	8
-32	-38	-10

// Zhang S, 2022: Zero Pronoun_GLM > Non-Zero Pronoun_GLM
// Zhang S, 2022: Zero Pronoun_MVPA > Rest
// Zhang S, 2022: Non-Zero Pronoun_MVPA > Rest
// Subjects=35
-50	-58	-14
-60	-20	6
5	-74	47
-11	-61	60
-24	43	37
-43	-80	34
-65	-30	-7
-27	65	9
52	-74	22
27	2	-29
-52	-42	-19
24	68	3
43	5	-48
33	-45	-23
30	-55	63
-21	15	-19
-5	59	-23
24	15	66
-5	46	41
14	-23	-35

// Castro M, 2020: Composers: familiar own music (OM) > unfamiliar other music 
// (UM) and familiar other music (FM) > UM
// Castro M, 2020: Composers: OM > UM
// Castro M, 2020: Composers: FM > UM
// Castro M, 2020: Composers: OM > FM
// Castro M, 2020: Composers: familiar own name after the presentation of 
// familiar own music (ONaOM) > familiar own name after the presentation of 
// unfamiliar other music (ONaUM)
// Castro M, 2020: Composers: ONaOM > familiar own name after the presentation 
// of familiar other music (ONaFM)
// Castro M, 2020: Composers: familiar other name after the presentation of 
// familiar own music (FNaOM) > familiar other name after the presentation of 
// unfamiliar other music (FNaUM)
// Castro M, 2020: Composers: FNaOM > familiar other name after the 
// presentation of familiar other music (FNaFM)
// Castro M, 2020: Composers: FNaFM > FNaUM
// Subjects=16
-8	-66	60
12	-64	56
28	4	64
-44	-40	38
54	-36	48
46	8	2
2	26	24
-14	-60	52
14	-62	52
26	2	56
-58	-34	52
54	-36	44
-58	10	18
4	-42	6
-4	-4	62
-60	4	26
-20	-62	-18
12	-62	46
28	2	66
-56	-32	34
60	-40	52
50	8	4
12	-34	26
12	-10	-4
-4	-6	-10
22	-50	36
-6	64	6
10	64	18
-52	0	40
-48	-42	-14
-2	-88	28
-32	-26	28
14	-60	48
-30	-36	40
-22	-74	-8
-20	-62	-18
-12	-40	64
22	-32	46
20	-58	42
18	-44	36
6	24	24
-50	-20	24
-4	-20	56
-30	-22	-16
-30	0	8
-12	-42	70
-34	-22	50
-12	-70	22
-12	6	34
28	2	6

// Bouhali F, 2022: Musicians
// Subjects=19
-53	-59	-9
-50	-52	-12

// Bouhali F, 2022: Non-musicians
// Subjects=21
-52	-60	-9
-47	-56	-13

// Koelsch S, 2021: Joy > Fear
// Subjects=24
48	-28	2
68	-25	11
52	-12	4
54	-24	20
38	-23	19
34	-24	10
54	-4	44
-48	-22	-2
-62	-13	-1
-48	-18	5
-38	-18	5
-54	-18	14
-34	-26	17
-48	38	20
-46	38	14
-48	0	54
-51	-28	59
21	32	52
0	56	5
15	-43	-43
-33	-58	-49
54	-64	5
-15	32	56
-6	11	65
-48	-64	-14
51	29	2
-27	-1	50
-15	-49	71

// Matthews T E, 2020: All Participants: Medium > High rythmic complexity
// Matthews T E, 2020: Musicians > Non- Musicians
// Subjects=25
-14	10	-2
-2	-2	8
22	4	8
-42	-48	44
-28	-58	40
-36	-54	40
-6	20	48
-4	12	52
-58	-40	-18
38	-58	50
34	-66	56
36	-50	38
-24	14	68
-8	-10	60
8	-4	68
34	6	52
58	-36	-16
-14	-92	-22
-40	26	28
-38	36	16
38	-68	16
6	-20	-44
0	-82	-12
-20	64	0
-28	0	50
-32	-60	-62
-14	26	-22
-22	24	-22
-12	32	28
-16	-18	72
4	-4	30
-46	8	32
12	-88	-28
-16	66	2
42	-50	-8
-36	6	46
-46	14	2
-46	-4	54
-38	-42	20
-40	-44	12
46	-6	48
-2	2	64
44	18	24
56	-8	6
-4	12	4
-58	-48	18
22	-12	32
56	-36	26

// Toiviainen P, 2020: Increased centrality during high beat salience
// Toiviainen P, 2020: Increased centrality during low beat salience
// Subjects=77
34	34	44
34	14	34
6	42	8
2	54	48
6	58	24
-18	34	72
-50	18	48
-38	10	60
-62	10	12
-10	-94	20
-50	22	4
46	-78	-16
58	-14	8

// Mungoven T J, 2022: Migraineurs (24 hr prior to migraine) > Healthy 
// Controls, Noxious heat > Baseline
// Subjects=7
-46	40	16
-52	24	29
-66	-48	75
-62	-20	22
-48	24	55
-48	10	20
10	6	23

// Baksa D, 2022: Study 1: Fear > Neutral, p=0.013
// Baksa D, 2022: Study 1: Fear > Neutral, Evening > Morning, p<0.001
// Baksa D, 2022: Study 1: Fear > Neutral, Evening > Morning, p=0.022
// Baksa D, 2022: Study 1: Fear > Neutral, Evening > Morning, p=0.013
// Baksa D, 2022: Study 2: Fear > Neutral, Morning > Varying
// Baksa D, 2022: Study 1: Fear > Neutral, p<0.001
// Baksa D, 2022: Study 1: Fear > Neutral, p=0.004
// Baksa D, 2022: Study 1: Fear > Neutral, p=0.006
// Baksa D, 2022: Study 1: Fear > Neutral, p=0.009
// Baksa D, 2022: Study 1: Fear < Neutral, p=0.006
// Baksa D, 2022: Study 1: Fear < Neutral, p=0.017
// Baksa D, 2022: Study 1: Fear < Neutral, p=0.001
// Baksa D, 2022: Study 1: Happy > Neutral, p<0.001
// Baksa D, 2022: Study 1: Happy > Neutral, p=0.014
// Baksa D, 2022: Study 1: Sad > Neutral, p<0.001
// Baksa D, 2022: Study 1: Sad > Neutral, p=0.035
// Baksa D, 2022: Study 1: Sad < Neutral
// Baksa D, 2022: Study 2: Fear > Neutral, p<0.001
// Baksa D, 2022: Study 2: Fear > Neutral, p=0.001
// Baksa D, 2022: Study 2: Fear < Neutral, p<0.001
// Baksa D, 2022: Study 2: Happy > Neutral, p<0.001
// Baksa D, 2022: Study 2: Happy > Neutral, p=0.013
// Baksa D, 2022: Study 2: Sad > Neutral, p<0.001
// Subjects=8
-57	-37	17
-45	-37	20
-51	-40	20
-63	-34	23
-45	-37	20
-57	-34	17
-60	-31	23
-51	-22	29
-60	-25	23
-57	-31	32
-60	-40	29
54	-19	11
45	-25	14
42	-28	11
48	-31	14
-9	-40	35
-9	-34	32
-15	-46	35
-18	-43	32
-12	-43	38
-6	-43	32
3	-46	41
6	-34	65
18	-31	74
9	-19	62
-3	-37	68
45	-46	-16
-36	-55	-13
45	-55	-13
-24	-94	8
-33	-73	-13
-27	-85	8
42	-70	-16
-30	-76	-19
-39	-67	-16
-39	-79	-10
39	-85	-1
36	-61	-7
42	-82	-4
-15	-88	-10
36	-70	-7
33	-88	5
21	-7	-13
30	-4	-19
33	-10	-10
30	-22	-4
48	11	35
45	26	23
45	11	29
51	32	29
57	23	26
-51	26	26
-48	20	29
-54	29	20
-57	26	14
-36	5	35
-36	11	35
-48	41	-4
-42	26	-16
-45	29	-13
-51	29	-10
-21	-4	-16
-3	38	50
9	23	53
-6	23	50
21	-46	8
-21	-49	5
3	-43	41
6	-34	41
-27	-88	11
-39	-79	-7
-30	-70	-4
-33	-76	-1
-33	-61	-7
-33	-73	-7
-36	-79	5
-39	-64	-7
-39	-70	-10
-15	-94	-1
-42	-58	-16
-27	-61	-10
-45	-49	-19
-27	-88	-7
-33	-88	-7
-27	-82	35
24	-88	8
39	-49	-16
36	-64	-10
39	-37	-22
48	-67	-7
24	-37	-25
6	-73	-1
18	-76	11
30	-70	29
30	-76	41
42	-70	17
9	-34	-28
54	-58	11
51	-73	8
-6	-37	-31
3	-34	-31
24	-1	-13
30	5	-22
27	-16	-10
42	32	11
42	26	20
48	32	14
48	26	20
42	5	23
39	8	29
39	8	35
54	29	20
57	23	23
-24	-4	-22
-27	-1	-16
-15	8	-13
-27	-70	-7
36	-82	2
-30	-85	17
-18	-82	-13
-27	-61	-7
-15	-94	17
45	-52	-13
-45	-52	-16
-42	-49	-7
-39	-85	5
21	-91	20
42	-37	-19
33	-61	-10
18	-79	-13
39	-67	-10
9	-85	-10
51	32	14
39	17	17
39	23	17
39	8	26
-42	-40	17
-63	-31	14
24	-79	-7
30	-91	8
33	-76	-10
39	-85	-1
-39	-46	-16
36	-85	-7
-27	-91	8
-21	-85	-7
-21	-88	-1
-33	-76	-10
3	-85	-7
-33	-85	-4
30	-61	-10
39	-49	-16
-42	-58	-10
12	-91	-4
54	38	8
42	17	23
42	23	20
36	8	23
39	-1	38
45	2	32
54	35	20
39	32	2
54	29	29
-33	5	29
-36	20	17
-51	11	20
-45	14	23
-57	14	11
-42	17	20
9	35	11
-15	50	2
0	32	23
-15	41	-1
6	32	-4
6	41	-7
9	35	-1
21	41	11
-3	41	5
6	44	17
-21	-94	11
-39	-76	-13
-36	-55	-16
-39	-85	2
-24	-82	-13
-27	-64	-10
-30	-67	-13
-9	-88	-10
30	-85	8
18	-97	17
21	-94	14
36	-52	-13
45	-61	-19
42	-52	-19
42	-76	-7
33	-76	-13
45	-73	-10
45	-82	2
24	-61	-7
51	-58	8
36	-61	56
27	-55	44
42	-34	-16
-9	-76	-40
-18	-70	-49
-24	-67	-49
24	-76	-10
45	-76	-1
39	-34	-19
-24	-70	-7
-24	-79	-10
-21	-82	-7
-24	-94	23
-36	-88	11
-33	-88	17
12	-94	11
-30	-85	8
-21	-82	-13
-39	-85	2
-36	-58	-13
-42	-82	-1
0	-88	-4
45	32	-4
54	38	8
48	38	14
42	11	20
30	2	-19
42	41	-13
39	2	38
42	26	17
51	-4	-13
45	20	-22
57	23	29
57	23	17
48	-7	-16
39	20	-28
51	8	-13
6	-34	-7
-48	35	11
-36	-1	32
-54	17	29
-45	17	-22
-51	-1	-16
-48	20	23
-39	32	-7
-42	20	-13
-39	17	26
-51	41	-7
-45	8	23
-36	14	-4
-24	20	-4
-45	53	-4
-54	20	2
-51	5	-22

// Brown S, 2021: Vocalization > Fixation
// Brown S, 2021: Jaw lowering > Fixation
// Brown S, 2021: Jaw clenching > Fixation
// Subjects=23
-42.35	-15.93	40.13
46.35	-15.4	39.07
50.62	-7.71	41.72
-58.39	-.79	44.62
60.25	-2.03	45.59
-42.35	-14.87	40.04
46.35	-15.4	39.07
63.41	-.32	39.84
-51.97	-12.82	39.98
47.27	-3.73	24.7
-51.89	-8.62	53.01
-40.23	-15.03	37.8
-57.31	-10.56	42.08
59.14	-6.86	38.21
-49.97	-5.37	25.95
-51.89	-8.62	53.01
-56.32	0.73	36.66

// Coccaro E F, 2022: Encoding: Intermittent Explosive Disorder (IED) < 
// Healthy Controls (HC)
// Coccaro E F, 2022: Attribution: IED < HC
// Coccaro E F, 2022: Emotional response: IED < HC
// Subjects=19
2	38	2
-62	-56	10
24	-88	-40
40	20	26
-42	24	26
-38	12	50
56	-44	-14
-16	26	62
-18	60	32
10	-24	-14

// Matt E, 2022: Migraine
// Subjects=10
-44	-38	34
48	-10	24
52	-28	24
-30	20	14
-32	-70	48
40	-62	50
64	28	-88
31	40	-62
38	26	-74
-44	-38	34
44	-74	30
22	32	50
28	-88	26
-14	-86	14
-4	-84	42
26	-80	-20
-18	-82	-22
-4	-96	-2
30	-78	-6
34	24	2
-32	20	10
28	-88	24

// Matt E, 2022: Healthy Controls
// Subjects=11
34	6	28
12	-82	18
34	24	2
-16	-48	-4
2	-84	14
-42	72	6
22	34	50
38	6	24
34	24	2
-32	20	10
28	-88	24

// Carollo A, 2023: Chinese > Arabic + Indian + Caucasian
// Carollo A, 2023: Chinese > Indian
// Carollo A, 2023: Chinese > Arabic
// Subjects=43
36	-70	2
39	-31	38
39	-31	38
30	-88	23
39	-73	-1
45	-61	-4
54	-67	-13
-39	-58	5
-39	-73	-1
33	-25	26
-3	-7	-4
-3	5	-7
27	-37	5

// Cui F, 2023: Scarcity > Abundance
// Cui F, 2023: Abundance > Scarcity
// Cui F, 2023: [(Scarcity in-group > Scarcity out-group) > (Abundance 
// in-group > Abundance out-group)]
// Cui F, 2023: Scarcity in-group > Scarcity out-group
// Subjects=28
14	-64	52
-22	-56	-26
-28	-60	-56
42	-34	40
6	0	54
48	6	28
-34	-46	44
-46	-68	4
-28	-60	40
-16	-92	-16
-24	-2	52
-38	-30	52
14	-56	-20
-14	-68	32
12	22	30
6	22	18
-2	34	22
2	40	26
-14	2	16
-20	-10	18
-8	56	30
2	-86	18
0	38	0
-2	34	8
20	46	32

// Farmer H, 2020: White > Black
// Farmer H, 2020: Face > Scrambled
// Subjects=25
-8	6	10
38	-42	-20
42	-58	-18
-38	-50	-26
-42	-86	-6
-6	18	48
42	28	22

// Handley G, 2023: White > Black
// Subjects=58
12	-99	15
15	-93	6
18	-81	15

// Li X, 2023: Experiment 2 Healthy Controls
// Subjects=40
-6	20	28
54	2	37
57	-61	4
3	32	25
60	-58	4
57	-4	37
51	-64	-8
-24	-94	-5

// Li X, 2023: Subgroup of Experiment 2 Healthy Controls, Mortality Salience
// Subjects=20
-6	20	40
57	-1	34

// Li X, 2023: Subgroup of Experiment 2 Healthy Controls, Negative Affect
// Subjects=20
36	-73	43

// Li Z, 2020: Group effect: In-group > Out-group
// Li Z, 2020: Observe > Commit
// Li Z, 2020: Commit > Observe
// Subjects=31
-27	47	-11
-36	14	-11
-6	26	34
36	17	-11
48	-25	52
12	14	58
0	-61	25
-60	-4	-26
54	-61	22
-45	-70	28
-24	23	46
0	56	-17
-57	29	4
-3	8	43

// Nugiel T, 2020: Ingroup > Outgroup
// Nugiel T, 2020: Outgroup > Ingroup
// Subjects=50
-18	-90	24
-8	34	-10
-50	-28	0
-36	-80	-22
-38	26	-8

// Rubien-Thomas E, 2021: Correct No-go > Correct Go
// Rubien-Thomas E, 2021: Go > No-go
// Rubien-Thomas E, 2021: Black Faces > White Faces
// Rubien-Thomas E, 2021: Black > White Participants in Black > White Faces
// Subjects=50
-32	-43	-24
-56	22	22
-8	42	50
52	-16	58
62	-50	42
-58	-60	38
6	-26	60
-54	-38	6
-42	-2	-32
62	-10	-14
-40	-20	50
16	-50	-20
20	-60	-46
-46	-4	8
-18	-70	-18
-56	4	24
42	-54	-14
32	20	4
-32	-42	-24
50	-70	28
-30	-84	40
-2	68	-6
8	-60	18

// van Gils S, 2023: Sacrifice Outgroup > Ingroup
// van Gils S, 2023: Handholding > Alone
// van Gils S, 2023: Condition x Block Interaction
// Subjects=17
-8.02	-100.09	22.26
10.97	-49.73	11.13
-17.55	-6.95	71.44

// Brignoni-Perez E, 2021: Arithmetic > Control, Monolinguals
// Brignoni-Perez E, 2021: Arithmetic > Control, Bilinguals
// Subjects=18
-30	22	-2
40	20	2
-6	12	50
-66	-46	14
52	-44	54
-46	-2	40
-26	-52	38
30	22	-2

// Declercq M, 2022: Untrained (UN) > Trained (TR), (Post-training)
// Declercq M, 2022: TR > Single Related (SR), (Pre-training)
// Declercq M, 2022: UN > SR, (Pre-training)
// Declercq M, 2022: UN > SR, (Post-training)
// Declercq M, 2022: SR > TR, (Pre-training)
// Declercq M, 2022: SR > UN, (Pre-training)
// Declercq M, 2022: SR > UN, (Post-training)
// Subjects=26
-34	-50	48
-42	-40	46
-28	-40	46
-6	-76	-30
-6	12	52
8	18	42
4	26	42
-42	2	32
28	8	56
52	16	34
-48	-56	-16
40	-42	46
42	-36	42
-38	-50	52
-30	-62	48
-34	-52	42
-30	-62	-28
-26	2	54
-22	-94	-4
-8	8	60
10	14	48
-50	-54	-12
28	-64	42
20	-66	44
34	-56	46
34	22	0
-4	10	52
10	20	40
6	16	52
-48	26	30
-40	4	34
-34	-48	42
-30	-56	52
-30	-62	46
-4	-70	-30
-38	-78	-14
38	18	-4
28	-64	-28
-54	-2	-18
0	56	-12
-56	-58	26
4	54	-8
-56	-4	-22
-8	50	8
-4	62	24
-2	-28	50
0	56	-16

// Matejko A A, 2021: Adults
// Subjects=26
40.9	-35	40.93
31.54	24.74	0.77
26.88	1.94	42.32
-3.51	19.76	43.52
2.41	-73.13	-25.3
-7.73	-83.55	3.59
-31.62	-46.72	41.65
-32.33	-63.62	-27.82
-30.82	1.26	43.74
-42.11	39.16	16.29
1.56	-61.2	25.55
42.95	4.91	23.75
29.9	-2.25	56.15
32.57	21.11	2.03
-30.11	-1.87	48.56
40.98	-34.78	41.1
33.11	22.67	0.65
-30.99	-44.24	42.3
-27.31	-1.14	52.57
68.15	-31.12	12.6
54.18	-54.55	20
39.47	-79.31	-4.32
1.32	-70.37	-31.89
-23.61	-44.93	39.2
-24.98	-70.28	28.89
-37.92	-80.62	-7.4
-27.04	-3.4	49.62

// Matejko A A, 2021: Children
// Subjects=38
36.19	-44.96	45.43
30.64	23.06	3.21
-.68	26.01	42.95
-40.52	-45.25	46.86
31.34	-60.31	35.13
50.18	8.5	28.2
29.38	0.15	55.85
5.9	-71.23	-17.92
14.84	-16.9	9.45
-18.03	0.2	49.82
-21.84	-56.69	49.56
-18.38	-26.93	8.91
-33.14	-80.7	7.44
-46.68	0.41	33.7
-45.64	-65.15	-2.17
35.27	-45.31	45.15
68.15	-31.12	12.6
54.18	-54.55	20
39.47	-79.31	-4.32
1.32	-70.37	-31.89
-23.61	-44.93	39.2
-24.98	-70.28	28.89
-37.92	-80.62	-7.4
-27.04	-3.4	49.62

// Newman S D, 2021: Structured Block Play
// Subjects=22
44	-36	6
38	-30	-6
-36	-30	6
-22	-16	6
6	-32	34
2	-18	32
-46	28	20
-42	-22	60
26	24	10
44	16	22
-42	-18	36
-32	-22	36
-26	-6	12
-36	-10	38

// Newman S D, 2021: Free Block Play
// Subjects=21
-52	-52	-2
-60	-34	26
-10	-52	50
-26	-6	12
-36	-10	38

// Qin S, 2024: Children
// Subjects=28
-32	16	2
40	20	-8
-38	20	26
40	20	22
-38	14	10
40	16	10
-2	6	56
-20	-40	-4
-20	-36	-2
24	-38	0
30	-20	-16
-46	-48	46
-36	-60	44
20	-100	0
-18	-2	2
12	-30	-18
-4	-52	-18
-26	-24	-16
-16	-20	-18
28	-18	-18
32	-14	-20
20	-68	-22
-44	18	52
-32	30	50
40	22	54
48	14	36
44	-72	26
-22	-64	64
46	32	40
44	42	34
-34	42	42
-30	40	40
-30	-68	54
-30	-76	50
32	-16	-18
14	-30	18
-40	16	34
-54	20	14
-42	-38	-16
40	-74	-14
62	-32	-8
-40	-18	44
-46	-22	36
-26	-14	-20
-22	-32	-2
20	-16	-16
32	-6	-18
-38	-8	-6
16	-66	18
-20	-30	0
10	-22	-2
-8	-32	-10

// Qin S, 2024: Adolescents
// Subjects=20
52	10	16
50	20	14
-38	4	26
10	12	42
46	10	2
36	20	-8
-2	18	48
-24	-66	48
32	-16	-18
14	-30	18
-40	16	34
-54	20	14
-42	-38	-16
40	-74	-14
62	-32	-8
-40	-18	44
-46	-22	36
-26	-14	-20
-22	-32	-2
20	-16	-16
32	-6	-18
-38	-8	-6
16	-66	18
-20	-30	0
10	-22	-2
-8	-32	-10

// Qin S, 2024: Adults
// Subjects=20
42	12	24
-46	6	28
-42	8	36
8	16	44
2	18	48
-32	-54	36
-24	-72	34
32	-16	-18
14	-30	18
-40	16	34
-54	20	14
-42	-38	-16
40	-74	-14
62	-32	-8
-40	-18	44
-46	-22	36
-26	-14	-20
-22	-32	-2
20	-16	-16
32	-6	-18
-38	-8	-6
16	-66	18
-20	-30	0
10	-22	-2
-8	-32	-10

// Su¨¢rez-Pellicioni M, 2021: Math Attitudes x Improvement in Small 
// Multiplication Problems
// Subjects=25
-12	-64	-6
30	-76	-16
30	-80	20
26	-82	28
6	-6	2
-4	-18	12

// Su¨¢rez-Pellicioni M, 2020: [(Large subtraction problems > Control) (Time 2 
// > Time 1) (Non-improvers > Improvers)]
// Subjects=23
-2	-81	22
-2	-91	18
2	-83	6
32	-33	38
40	-35	46
44	-23	42
-38	-53	6
-36	-65	2
-36	-67	22

// Bi R, 2022: High effort > Low effort, All Participants
// Bi R, 2022: Other > Self, All Participants
// Bi R, 2022: Healthy Control (HC) [self] - HC[other] > Subthreshold 
// Depression (SD) [self] - SD[other]
// Bi R, 2022: high[self] - high[other] > low[self] - low[other], All 
// Participants
// Bi R, 2022: High effort > Low effort, All Participants (TFCE-FWE)
// Bi R, 2022: Other > Self, All Participants (TFCE-FWE)
// Bi R, 2022: (HC[self] - HC[other] > SD[self] - SD[other]), All Participants 
// (TFCE-FWE)
// Bi R, 2022: (high [self] - high [other]) > (low [self] - low [other]), All 
// Participants (TFCE-FWE)
// Subjects=30
20	-8	64
-20	-10	68
30	-10	62
-18	-18	24
-16	-26	22
-14	-8	24
20	-24	22
-18	18	16
-16	10	20
14	48	24
18	40	46
30	40	-16
30	54	-12
16	52	-4
-30	36	-16
-28	46	-6
38	-54	22
-18	50	8
-12	40	30
14	32	42
-12	8	60
-60	-12	-24
-54	30	-2
-50	40	-8
-52	-28	6
-12	-16	42
66	-14	-2
-8	38	54
2	56	38
46	-24	56
-30	18	-18
-36	16	-10
32	16	-12
-48	24	14
-44	18	10
48	30	0
50	10	10
56	16	10
-42	-36	22
-4	40	22
-2	50	30
6	36	4
10	40	16
-58	-48	36
-32	28	34
-14	-46	42
-16	-44	34
52	10	-16
44	18	-30
2	56	-14
-34	-10	18
-50	8	-14
-68	-22	2
28	-72	-38
-18	-82	-30
14	64	26
-10	36	38
-6	56	38
62	14	14
56	10	4
-54	32	-2
-52	40	6
24	18	38
46	14	52
6	-14	56
10	-14	74
28	-16	64
38	-56	24
38	-58	36
2	64	12
29	-46	2
12	10	18
14	-2	20
8	16	10
-12	46	18
-36	10	32
-6	-70	-44
24	56	2
28	48	12
48	40	4
58	32	8
40	36	-12
44	28	-8
-4	-60	66
-30	8	40
54	-44	30
60	-46	42
58	-50	24
4	42	18
-30	20	44
-30	42	40
-28	34	50
-38	32	-16
-30	24	-16
-28	-80	42
-36	-84	34
-14	2	52
-34	-70	26
42	-18	-26
50	-42	-18
30	-14	-18
2	-60	-48
14	44	16
54	-32	40
-36	4	64
-50	-74	-6
-58	10	18
-50	-52	6
22	-40	62
-64	-50	12
-64	-54	2
-22	-68	62
-34	50	0
56	-66	18
26	34	44
28	30	52
24	-70	46
34	-70	54
-52	-64	-14
52	-64	32
-22	-64	-44
-16	0	62
20	-70	62
-8	-14	42
-44	-66	-36
34	-86	28
-60	-40	32
20	-8	64
30	-10	62
30	-18	64
-34	-82	-22
-32	-82	-42
-40	-74	-22
16	26	-2
22	18	16
6	16	4
38	-54	22
-30	18	-18
-30	16	-10
-46	22	14
32	16	-12
48	28	0
50	10	10
-4	40	22
-2	50	30
10	40	16
-6	20	54
-12	18	62
4	24	60
-24	50	24
-30	56	24
-22	52	16
-32	28	34
-14	-46	42
52	10	-16
42	-12	-12
-60	-14	22
-68	-22	2
-50	8	-14
-18	-82	-30
-24	-90	-34
-30	-82	-44
-6	56	38
-6	58	22
-12	64	20
28	-72	-38
30	-66	-44
30	-82	-36
-54	32	-2
-50	42	-12
-52	40	6
26	18	38
44	18	46
26	34	44
-4	-60	66
-4	-58	56
38	-56	24
38	-58	36
-36	-24	-10
-30	8	40
-38	8	42
-24	0	46
-22	-68	62
-14	-76	60
54	-44	30
60	-46	42
-50	-74	-6
-52	-64	-16
-54	-62	-8
-60	-40	32
-46	-40	34
-48	-32	36
-36	4	64
-32	-80	4
-44	-84	0

// Culbreth A J, 2020: Main Effect of Task (Hard > Easy Decisions) for All 
// Groups, p<0.01
// Culbreth A J, 2020: Main Effect of Task (Hard > Easy Decisions) for All 
// Groups, p=0.02
// Culbreth A J, 2020: Main Effect of Task (Hard > Easy Decisions) for All 
// Groups, p=0.04
// Subjects=28
-46	-80	-6
40	-82	-18
-34	-26	75
0	14	48
-26	-80	45
8	-58	9

// Prettyman G E, 2021: Whole-brain activation during task correlated with 
// clinical amotivation across all participants
// Prettyman G E, 2021: Healthy Controls > Schizophrenia
// Subjects=21
6	12	2
6	16	2
-14	8	-6

// Pretus C, 2021: Group (HC > SZ) x reward (high > low), p=0.06
// Pretus C, 2021: Group (HC > SZ) x reward (high > low), p=0.001
// Pretus C, 2021: Group (HC > SZ) x effort (high > low), p=0.009
// Pretus C, 2021: Group (HC > SZ) x effort (high > low), p<0.001
// Subjects=20
-18	24	12
-26	18	20
-16	34	14
18	12	22
22	30	18
30	14	22
-18	24	12
-24	-2	28
-26	18	20
30	12	22
18	8	26
24	30	20

